NORDTREAT
3.9.2024 06:51:33 CEST | Business Wire | Press release
The Finnish technology company Nordtreat strengthens its growth by appointing Outi Kallio as the new CEO. Her era at Nordtreat will start from the turn of 2024/2025. Outi Kallio has a wealth of experience in commercial and industrial management, having held several key positions at Teknos Group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240902513997/en/
The Finnish technology company Nordtreat strengthens its growth by appointing Outi Kallio as the new CEO. (Photo: Business Wire)
Outi Kallio has an extensive background in sales, HR, and marketing. She also has a proven track record of leading international teams. Currently, she holds the position of Global Commercial Director at Teknos Group.
"As Nordtreat continues to grow and evolve, we are thrilled to welcome Outi Kallio as our new CEO. Her diverse experience and proven leadership skills make her the ideal candidate to lead Nordtreat into its next chapter. We believe that Outi Kallio’s strategic vision and operational expertise will drive our company forward and enhance shareholder value," says Leif Frilund, Chairman of the Board of Nordtreat.
"With over a decade of experience in the coatings industry, I have seen a growing shift towards sustainable solutions, driven by increasing customer expectations. Nordtreat's commitment to bio-based technologies and its strong ethos of responsibility provides a solid foundation for scaling Finnish sustainability expertise into an international growth story. I am excited to join this team of top professionals and look forward to contributing to our shared success," Outi Kallio says.
As Nordtreat’s CEO, Outi Kallio will succeed Aki Borgentorp, who has led the company for ten years. These years have included the development of the first truly bio-based flame retardant for wood-based materials and the growth of a worldwide market presence.
"Over the past decade, Nordtreat has built a scalable platform for the development and production of bio-based flame retardants for wood-based materials. I am convinced that under Outi Kallio’s leadership, Nordtreat will continue to innovate and expand its presence in the market and make a significant impact in the construction materials industry," says Aki Borgentorp.
"On behalf of the Nordtreat board, I’d like to express our sincere gratitude to Aki Borgentorp for his remarkable achievement in building Nordtreat from scratch into a leading provider of new sustainable flame-retardant solutions. We wish Aki the best of success in his future endeavours," Leif Frilund says.
Nordtreat has also welcomed Dr Thomas Kostka, the Head of Corporate Venturing at Altana AG, to join the board of directors starting in August 2024. Additionally, Nordtreat has appointed Sakari Saarela, a partner in the UB FIGG Fund, as a board observer. Sampsa Auvinen, who has been on Nordtreat's board since 2022, will continue as UB FIGG's representative on the board. Sampsa Auvinen is also the Chairman of the Advisory Board of UB FIGG. Altana Group, the global leader in true specialty chemicals, and the Finnish sustainability fund UB Forest Industry Green Growth Fund (UB FIGG), a growth private equity fund investing in sustainable and resource-efficient forest and bio-based industries, announced an investment in Nordtreat in June 2024.
"We are happy to welcome Thomas Kostka to the board of directors at Nordtreat. He brings us a deep understanding of the industry and strategic insights that will be invaluable as we continue to grow," says Leif Frilund.
Nordtreat is a Finnish technology company founded in 2015, specializing in the development and production of environmentally friendly, high-performance flame retardants. Utilizing bio-based raw materials, Nordtreat's products comply with the latest fire protection regulations and have been used to protect over 2000 buildings worldwide. The company's flagship technology, NORFLAM®, is designed to provide superior fire protection while maintaining environmental sustainability. Nordtreat's innovative solutions are aimed at meeting the growing global demand for safer, more sustainable construction materials. www.nordtreat.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240902513997/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st
Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys20.4.2026 16:00:00 CEST | Press release
Industry’s most widely adopted PETG material meets industry-leading cleanliness, compliance, and RNase/DNase-free validation—now available across the full bioprocessing workflow. SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with SaniSure’s proprietary process and advanced automation. This launch expands SaniSure’s established PharmaTainer® platform—extending its proven cleanliness, robustness, and performance attributes to include industry-standard PETG alongside its existing PET and PC offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420641769/en/ PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bioprocessing applications. Available in volumes from 10 mL stability vials to 10 L carboys — in sterile (gamma-irradiated) an
Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 15:08:00 CEST | Press release
Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 15:00:00 CEST | Press release
– Highly innovative and original gameplay earns strong reception from players around the globe – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broade
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom